-
FDA Approves Gilead's Remdesivir For Treatment Of Hospitalized COVID-19 Patients
Thursday, October 22, 2020 - 4:42pm | 409Read More...The U.S. Food and Drug Administration has approved the antiviral Veklury, commonly known as remdesivir, for the treatment of hospitalized patients with COVID-19. What Happened: Gilead Sciences' (NASDAQ: GILD) remdesivir is approved for patients that are at least 12 years of age. The...
-
Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development
Monday, September 14, 2020 - 4:23pm | 742Read More...Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease. Gilead CEO On Remdesivir: Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir received an emergency use authorization designation in...
-
Gilead Ticks Higher After Q2 Earnings Beat
Tuesday, July 30, 2019 - 4:20pm | 272Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares are slightly higher after reporting a second-quarter earnings beat. Adjusted earnings came in at $1.82, beating estimates by 10 cents. Sales came in at $5.685 billion, beating estimates by $175 million. The company raised 2019 product sales guidance from...
-
New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James
Tuesday, December 11, 2018 - 3:49pm | 401Read More...Research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced Monday it has named Daniel O'Day as its chairman of the board and CEO, effective March 1. What Happened O'Day joins Gilead after more than three decades of experience at Roche Holdings AG Basel ADR (OTC...
